Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155202 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL10970382 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL890546 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL15558392 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL3144947 | 0.77 | FADS1 (0.40) | KDM4EALDH1A1GAAHTT | |
| SCHEMBL3146184 | 0.76 | MAPK1 (0.43) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL8519386 | 0.76 | KMT2A (0.53) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL30402668 | 0.76 | KDM4E (0.51) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL298328 | 0.75 | NPC1 (0.54) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL297730 | 0.75 | ALDH1A1 (0.50) | KDM4EALDH1A1GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636225-B1 | PYRIDINO 1,2-A PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1636225-B1 | PYRIDINO 1,2-A PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7662581-B1 | Eg5 co-crystals | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662581-B1 | Eg5 co-crystals | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662581-B1 | Eg5 co-crystals | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7504405-B2 | Mitotic kinesin inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504405-B2 | Mitotic kinesin inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | CHIRON CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-7326711-B2 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326711-B2 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326711-B2 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1732926-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1636225-A2 | PYRIDINO 1,2-A PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005100357-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228002-A1 | Mitotic kinesin inhibitors | CHIRON CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050085490-A1 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORPORATION | 2005-04-21 | — | — | US | disclosed |
| WO-2004113335-A2 | PYRIDINO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | KIF5B, KIF2C, KIFC1 | KDM4E 818/4885ALDH1A1 2701/4885GLA 2860/4885 |
| US-20050085490-A1 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | TYMP, DPYD, TK1 | KDM4E 3300/4885ALDH1A1 290/4885GLA 1932/4885 |
| US-20050228002-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | KDM4E 818/4885ALDH1A1 2701/4885GLA 2860/4885 |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIFC1 | KDM4E 810/4885ALDH1A1 2363/4885GLA 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.